5/15
10:46 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Citigroup Inc. from $8.00 to $4.00. They now have a "buy" rating on the stock.
Low
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Citigroup Inc. from $8.00 to $4.00. They now have a "buy" rating on the stock.
5/14
08:07 pm
allo
Allogene's Q1 Earnings In Line With Estimates, Sales Nil [Yahoo! Finance]
High
Report
Allogene's Q1 Earnings In Line With Estimates, Sales Nil [Yahoo! Finance]
5/14
12:41 pm
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Piper Sandler from $9.00 to $7.00. They now have an "overweight" rating on the stock.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Piper Sandler from $9.00 to $7.00. They now have an "overweight" rating on the stock.
5/14
12:41 pm
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Truist Financial Co. from $14.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Truist Financial Co. from $14.00 to $10.00. They now have a "buy" rating on the stock.
5/14
11:13 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
5/14
10:30 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $10.00 to $9.00. They now have an "outperform" rating on the stock.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $10.00 to $9.00. They now have an "outperform" rating on the stock.
5/14
09:12 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Robert W. Baird from $12.00 to $9.00. They now have an "outperform" rating on the stock.
High
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Robert W. Baird from $12.00 to $9.00. They now have an "outperform" rating on the stock.
5/14
09:11 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) was downgraded by analysts at Citizens Jmp from an "outperform" rating to a "market perform" rating.
High
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) was downgraded by analysts at Citizens Jmp from an "outperform" rating to a "market perform" rating.
5/13
04:05 pm
allo
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
High
Report
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
5/6
08:50 am
allo
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update [Yahoo! Finance]
Neutral
Report
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update [Yahoo! Finance]
5/6
08:30 am
allo
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
High
Report
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
4/23
11:02 am
allo
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Low
Report
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
4/23
10:12 am
allo
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Medium
Report
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
4/7
08:30 am
allo
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
Medium
Report
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
3/19
08:04 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
3/14
11:49 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
Low
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
3/14
11:49 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
Low
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
3/14
07:15 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) was upgraded by analysts at Citizens Jmp from a "market perform" rating to an "outperform" rating. They now have a $5.00 price target on the stock.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) was upgraded by analysts at Citizens Jmp from a "market perform" rating to an "outperform" rating. They now have a $5.00 price target on the stock.
3/13
08:07 pm
allo
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update [Yahoo! Finance]
Low
Report
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update [Yahoo! Finance]
3/13
04:02 pm
allo
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
Low
Report
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
3/3
08:30 am
allo
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Medium
Report
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
2/27
05:48 pm
allo
Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia [Yahoo! Finance]
Low
Report
Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia [Yahoo! Finance]
2/26
10:53 am
allo
https://seekingalpha.com/article/4762166-allogene-assessing-the-pipeline-competitive-landscape-and-opportunities [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4762166-allogene-assessing-the-pipeline-competitive-landscape-and-opportunities [Seeking Alpha]
2/26
08:30 am
allo
Allogene Therapeutics Announces Participation in March Investor Conference
Low
Report
Allogene Therapeutics Announces Participation in March Investor Conference
2/25
04:10 pm
allo
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
Low
Report
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia